OTC · GENX
Genex Pharmaceutical, Inc.
$0.00+$0.00 (+100.0%)
Genex Pharmaceutical, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
Loading market information…
OTC · TBET · USD
Stock price
Quote as of Dec 30, 2025, 09:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Tibet Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE COMPANY BEHIND THE TICKER
Tibet Pharmaceuticals, Inc. operates as a specialized pharmaceutical company, primarily focused on the research, development, manufacturing, marketing, and distribution of traditional Tibetan medicines. The company conducts its core activities through its operational subsidiary, Yunnan Shangri-La Tibetan Pharmaceutical Group Limited (YSTP), which develops products within China to support the health of human respiratory, digestive, urinary, and reproductive systems. Among its currently commercialized products are: 25 Ingredients Mandrake Pill: Used for menstrual regulation and to address conditions like endometritis, pelvic inflammations, and anemia in women. 15 Ingredients Gentiana Pill: Prescribed for respiratory ailments including bronchitis, emphysema, asthma, and hoarseness. 28 Ingredients Pinang Pill: Aims to alleviate cold waist and hip pain, pus hematuria, and testicular swelling. 18 Ingredients Chebulic (Myrobalan) Frusemide Pill: Designed to treat various kidney issues, lower back and kidney pain, frequent or turbid urination, diabetes, and spermatorrhea. Pomegranate Nichirin Pill: Helps manage indigestion, back and leg pain, frequent urination, foot edema, impotence, and nocturnal emissions. The company also maintains an active development pipeline. The Xuezang Guben pill is being developed for neurasthenia, insomnia, frequent urination, nocturnal emission, and menopausal symptoms. Shengke I is currently in Phase III clinical testing for type II diabetes, while Shengke II is in Phase II trials, exploring its potential for impotence, premature ejaculation, prostate disease, and memory loss. The Jiuzan pill, also a Phase II candidate, targets chronic gastroenteritis and peptic ulcers. Additionally, Antai pill is a pre-clinical stage product under investigation for hepatitis B. Tibet Pharmaceuticals further plans to commercialize Wupeng Pill, intended for a range of conditions including echinococcosis, pandora tingling disease, diphtheria, anthrax, yellow water disease, and leprosy. Incorporated in 2009, the company was initially known as Shangri-La Tibetan Pharmaceuticals, Inc., before officially changing its name to Tibet Pharmaceuticals Inc. in July 2010. Its headquarters are located in Wanchai, Hong Kong.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:05 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.00+$0.00 (+100.0%)
Genex Pharmaceutical, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00-$0.00 (0.0%)
Aamaxan Transport Group, Inc.’s quoted price sits in the lower half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
ThermoGenesis Holdings, Inc.: Healthcare · Medical - Devices.
$0.00$0.00 (0.0%)
9 Meters Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.0% below the high.
$0.00$0.00 (0.0%)
Oracle Healthcare Acquisition Corp.: Financial Services · Shell Companies.
$0.00$0.00 (0.0%)
Millennium Sustainable Ventures Corp.’s quoted price sits in the lower half of its reported 52-week range, 75.0% below the high.
$0.00$0.00 (0.0%)
DMK Pharmaceuticals Corporation’s quoted price sits in the lower half of its reported 52-week range, 90.0% below the high.
$0.00$0.00 (0.0%)
BioELife Corp.’s quoted price sits in the lower half of its reported 52-week range, 66.67% below the high.
